Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach

Area of Science:

• Cardiovascular Medicine
• Translational Science

Background:

• Statins effectively lower LDL cholesterol and reduce cardiovascular events.
• Residual cardiovascular risk persists despite statin therapy, necessitating novel approaches.
• Epidemiological studies show an inverse relationship between HDL cholesterol and coronary heart disease risk.

Purpose of the Study:

• To explore HDL-based therapies as an adjunct or alternative to statins for atherosclerosis management.
• To evaluate the potential of direct HDL infusion for atherosclerosis stabilization and regression.

Main Methods:

• Review of pre-clinical studies on HDL-based therapies.
• Analysis of preliminary clinical data on HDL infusion efficacy and feasibility.

Main Results:

• Pre-clinical data suggest HDL-based therapies can stabilize or regress atherosclerosis.
• Preliminary clinical studies indicate the feasibility of direct HDL infusion.

Conclusions:

• Direct HDL infusion represents a potential new therapeutic paradigm for atherosclerosis.
• HDL-based therapies warrant further investigation for managing atherosclerotic cardiovascular disease.